Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | TACR1 | P25103 | 3/20 | 0.44 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14763553 | 1.00 | SLC1A1 (0.49) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL28538137 | 0.88 | SLC1A1 (0.49) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL28538138 | 0.88 | SLC1A1 (0.49) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL20741434 | 0.85 | SRR (0.41) | SLC1A1SRREPHX1TSHRALPI | |
| SCHEMBL28909574 | 0.80 | SLC1A1 (0.43) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL28909576 | 0.80 | SLC1A1 (0.43) | SLC1A1CA1CA2CA7CA9 | |
| SCHEMBL28435578 | 0.80 | SRR (0.47) | SLC1A1SRREPHX1ALPIPKM | |
| SCHEMBL375856 | 0.80 | SRR (0.47) | SLC1A1SRREPHX1ALPIPKM | |
| SCHEMBL28432031 | 0.80 | SRR (0.47) | SLC1A1SRREPHX1ALPIPKM | |
| SCHEMBL29011373 | 0.80 | SRR (0.47) | SLC1A1SRREPHX1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| US-8992932-B2 | Binder-drug conjugates (ADCs) and use thereof | SEATTLE GENETICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150030618-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150023989-A1 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | SEATTLE GENETICS, INC. | 2015-01-22 | — | — | US | disclosed |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | Bayer Pharma AG (DE) | 2013-04-18 | — | — | US | disclosed |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | MDN1, EPCAM, VCAM1 | SLC1A1 3016/4885CA1 1904/4885CA2 2061/4885 |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | SLC1A1 2609/4885CA1 3280/4885CA2 2552/4885 |
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | SLC1A1 2609/4885CA1 3280/4885CA2 2552/4885 |
| US-20150023989-A1 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | FGFR2, FGFR1, FGFR3 | SLC1A1 1828/4885CA1 1970/4885CA2 2220/4885 |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | DDR1, IGFBP6, KDR | SLC1A1 1490/4885CA1 4466/4885CA2 3387/4885 |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | DDR1, IGFBP6, KDR | SLC1A1 1490/4885CA1 4466/4885CA2 3387/4885 |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | CDK4, CDKL4, FLT4 | SLC1A1 2609/4885CA1 3280/4885CA2 2552/4885 |
| US-20150030618-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | SLC1A1 2631/4885CA1 3393/4885CA2 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.